Allurion's High-Stakes Reverse Split: A Bid to Reclaim Wall Street

NATICK, MA – June 17, 2026 – Allurion Technologies, a company aiming to revolutionize weight loss with its swallowable gastric balloon, is making a bold financial maneuver to regain its footing on Wall Street. The company announced it will execute a 1-for-15 reverse stock split, set to take effect at midnight. The move is a calculated gambit designed to boost its per-share price and pave the way for a return to a major national stock exchange.

Since being delisted from the New York Stock Exchange earlier this year, Allurion has traded on the over-the-counter market, a less visible and liquid environment for public companies. This reverse split is the cornerstone of a plan to reverse that trajectory. By consolidating its shares, Allurion hopes to meet the minimum bid price requirements of either the NYSE or the NYSE American, a critical step in its bid for re-listing.

“We have had a constructive and collaborative dialogue with the national exchanges throughout this process, and we remain focused on meeting all requirements necessary to regain our listing,” said Dr. Shantanu Gaur, Founder & CEO of Allurion. “We believe re-listing will enhance our visibility, improve liquidity for our shareholders, and better position Allurion for long-term growth as we continue to execute on our U.S. commercial strategy.”

The Road to the OTC Markets

To understand the necessity of this move, one must look back at Allurion's recent history. The company's journey to the OTCQB market was not sudden. In March 2026, the NYSE initiated delisting proceedings after the company's stock failed to maintain an average global market capitalization of at least $15 million over 30 consecutive trading days, a key continued listing standard under Section 802.01B of the exchange's manual. Trading was suspended on March 6, 2026.

This followed an earlier warning in August 2024, when the NYSE first flagged Allurion for non-compliance. At that time, its average market capitalization over a 30-day period had fallen below $50 million while its stockholders' equity was also under the same $50 million threshold. These events paint a picture of a company whose market valuation struggled to keep pace with its operational ambitions, forcing it off the main stage and into the less prestigious OTC markets.

For a company with an innovative, FDA-approved medical device poised for a major U.S. launch, the diminished visibility and liquidity of the OTC market is a significant handicap. This reverse split is a direct and aggressive response to that challenge.

A Financial Reset Button

The mechanics of the reverse split are straightforward but have significant implications. Effective June 18, every fifteen shares of Allurion's common stock will be consolidated into a single share. This will reduce the number of outstanding shares from approximately 15 million to just over 1 million. Consequently, the stock's price should, in theory, increase fifteen-fold, elevating it well above the typical $1.00 minimum bid price required by major exchanges.

The stock will trade under the temporary symbol “ALURD” for 20 days to signify the corporate action before reverting to its original “ALUR” ticker. In a shareholder-friendly move, the company has stated that no fractional shares will be issued; instead, any resulting fractions will be rounded up to the next whole share.

This financial restructuring extends beyond common stock. Proportional adjustments will be made across the company's entire capital structure, including to equity incentive plans, outstanding stock options, and convertible notes. Warrants will also be adjusted significantly. For instance, public warrants that were previously exercisable for a fraction of a share will now be exercisable for an even smaller fraction (0.00378787 shares) but at a correspondingly massive exercise price of $3,037.50 per share. This demonstrates a comprehensive effort to reset the company's equity framework in a way that is compliant and logically consistent post-split. While reverse splits are often viewed with skepticism by investors as a sign of distress, Allurion is framing this as a strategic enabler for its next growth phase.

Fueling the U.S. Commercial Engine

The true test of this strategy lies not in the financial engineering itself, but in whether it can successfully fuel Allurion's core business. The timing is crucial, coming just months after the company secured a landmark U.S. Food and Drug Administration (FDA) approval on February 20, 2026, for its Allurion Gastric Balloon System. This approval unlocked the largest weight loss market in the world for its flagship product—a swallowable, procedure-less gastric balloon.

A re-listing on the NYSE or NYSE American would be a powerful catalyst for its U.S. commercial strategy. The enhanced credibility and visibility of a major exchange listing can attract a wider pool of institutional investors, providing better access to the capital needed for marketing, sales force expansion, and further R&D. It also boosts a company's profile with healthcare providers and potential strategic partners.

Allurion is more than just a balloon. The company's Allurion Program is an integrated platform combining the device with a Virtual Care Suite, which includes a mobile app, the Iris AI platform for patient support, and data insights for clinicians. The firm is also exploring combination therapies, having announced a partnership to offer its program alongside GLP-1 drugs like Mounjaro®. This positions Allurion not just as a device maker, but as a comprehensive weight management company—a narrative that is much easier to sell to the market from the platform of a major exchange.

Navigating a Treacherous Path Forward

Executing the reverse split is only the first step on a difficult path. The primary challenge will be to ensure the newly elevated stock price holds its ground. Market history is littered with companies that executed reverse splits only to see their share price subsequently erode back toward non-compliance levels. Sustaining the price will require more than just a smaller share count; it will require tangible business execution.

To successfully re-list, Allurion will not only have to maintain a minimum bid price but also meet other quantitative standards for market capitalization and stockholders' equity for a sustained period. The bar for entry is also rising, with exchanges like NYSE American proposing stricter rules, such as a potential $4.00 minimum initial listing price and immediate suspension for stocks falling below $0.25.

Ultimately, investor confidence will hinge on the company's financial performance. Allurion's full-year 2024 results showed procedure volume growth but also pressure on gross margins, which fell from 78% to 45% in the fourth quarter, attributed to market headwinds and a temporary sales suspension in France. While the company has taken steps to shore up its balance sheet, its ability to successfully commercialize its product in the U.S. and translate that into strong revenue growth and profitability will determine whether this reverse split is remembered as a turning point or a temporary fix.